659. Can Marty Makary Fix the F.D.A.?

The conversation centers on Marty Makary's role as FDA Commissioner and his efforts to modernize the agency. Makary discusses addressing over-regulation, streamlining drug approval processes, and leveraging AI to improve efficiency. He highlights initiatives such as making FDA decision letters public and redefining baby formulas to promote innovation. The discussion touches on controversies, including the FDA's stance on acetaminophen use during pregnancy and direct-to-consumer pharmaceutical ads. Makary also addresses funding for public health and the challenges of navigating political influences on scientific decisions, particularly concerning vaccine efficacy and the phenomenon of "Trump Derangement Syndrome."